Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
BJU International
|
April 28, 2021
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration
Praful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer
|
April 17, 2026
LuRa: Efficacy and Safety of Radium-223 Following [<sup>177</sup>Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Jabra Zarka, Ronit Juthani, Oliver Sartor, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 24, 2022
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy
Angelika Terbuch, Florian Posch, Thomas Bauernhofer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2023
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study
Luca Antonelli, Davide Ardizzone, Praful Ravi, et al.
Clinical Genitourinary Cancer
|
August 31, 2024
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study
Giuseppe Fotia, Calogero Saieva, Richard Lee-Ying, et al.
Clinical Genitourinary Cancer
|
October 26, 2024
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study
Anna Patrikidou, Calogero Saieva, Richard Lee-Ying, et al.
European Urology
|
November 5, 2025
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis
Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Kunwer Sufyan Faisal, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 27, 2024
Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]
Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 7, 2024
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States
Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, et al.
Cancer
|
June 17, 2024
Insulin resistance during androgen deprivation therapy in men with prostate cancer
Shehzad Basaria, Mary-Ellen Taplin, Marie McDonnell, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
BJU International
|
April 28, 2021
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration
Praful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer
|
April 17, 2026
LuRa: Efficacy and Safety of Radium-223 Following [<sup>177</sup>Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Jabra Zarka, Ronit Juthani, Oliver Sartor, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 24, 2022
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy
Angelika Terbuch, Florian Posch, Thomas Bauernhofer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2023
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study
Luca Antonelli, Davide Ardizzone, Praful Ravi, et al.
Clinical Genitourinary Cancer
|
August 31, 2024
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study
Giuseppe Fotia, Calogero Saieva, Richard Lee-Ying, et al.
Clinical Genitourinary Cancer
|
October 26, 2024
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study
Anna Patrikidou, Calogero Saieva, Richard Lee-Ying, et al.
European Urology
|
November 5, 2025
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis
Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Kunwer Sufyan Faisal, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 27, 2024
Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]
Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 7, 2024
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States
Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, et al.
Cancer
|
June 17, 2024
Insulin resistance during androgen deprivation therapy in men with prostate cancer
Shehzad Basaria, Mary-Ellen Taplin, Marie McDonnell, et al.
Page
of 11